Signal An estimated $79.4 billion of public investment built the mRNA infrastructure now reused

Summary

The chapter attributes the field's momentum to infrastructure built during the COVID-19 pandemic, which turned mRNA from a research platform into global manufacturing and regulatory capacity and compressed years of development into months, backed by an estimated $79.4 billion of public investment across vaccine development programmes.